Industry expert's pharmaceutical and healthcare report, “” is an essential source of information and analysis on the global Erectile Dysfunction (ED) therapeutics industry . The report identifies the major industry developments shaping and driving the ED industry . The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing industry leaders. Most importantly, the report provides valuable insight on the new product development within the global ED therapeutics segment .

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

The ED industry is currently very competitive and is expected to become more competitive in the future. The industry is dominated by three major cyclic Guanosine Monophosphate (cGMP)-specific Phosphodiesterase type 5 (PDE5 inhibitors) including Viagra (sildenafil citrate), Cialis (tadalafil) and Levitra (vardenafil HCl). The industry is expected to witness a decline between 2011 and 2014 due to patent expiry of the blockbuster drug Viagra. Viagra’s patent expires in early 2012 and the industry is expected to decline due to erosions of margins with the entry of generics. Post 2014, the industry is expected to grow due to an increase in the number of ED patients. Industry expert's analysis revealed that the industry grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among the male general population to discuss their sexual problems. With the patent expiry of Viagra in 2012, the industry is expected to decline after 2011, with a CAGR of 3.2% 2009-2017 .

Industry expert's analysis showed that the ED pipeline is weak. The products in the ED pipeline comprise of me-too molecules. Some of the promising me-too class drugs/molecules are in Phase III trials and are likely to get approval in coming years. One of the promising molecules is Avanafil, which is unlikely to have much impact as the industry has high competition among similar products and will experience generic erosion after 2012 due to patent expiry of Viagra.

Scope of the Research

The Scope of the Research of the report includes:
- Annualized global ED therapeutics industry revenues data from 2001 to 2009, projection forward for eight years to 2017.
- Pipeline analysis data providing an overview of the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include serotonin and dopamine enhancers, PDE-5 inhibitors and Alpha1A-adrenoreceptors antagonisst.
- Analysis of the current and future industry competition in the global ED therapeutics industry . Key industry players covered are VIVUS, Inc., Palatin Technologies, Inc. and Rexahn Pharmaceuticals, Inc.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs, and the implications for the future industry associated with ED.

Why Should You Get This Report?

The report will enhance and speed up your decision making capability and will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies, and by identifying industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ED therapeutics industry .
- Drive revenues by understanding major industry developments, innovative products and technologies, industry sectors, and industry players likely to impact the global ED therapeutics industry in the future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments, and strategic partnerships.
- What’s the next big thing in the global ED industry landscape? Identify, understand, and capitalize

Table Of Contents

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 4
I. 2 List of Charts 4

II Erectile Dysfunction: Introduction 5
II. 1 GlobalData Pipeline Report Guidance 5

III Erectile Dysfunction: March ket Characterization 6
III. 1 Erectile Dysfunction March ket Size 6
III. 2 Erectile Dysfunction March ket Forecasted data and CAGR 6
III. 3 Drivers and Barriers for the Erectile Dysfunction March ket 7
III. 3.1 Drivers of the Erectile Dysfunction March ket 7
III. 3.2 Barriers for the Erectile Dysfunction March ket 8
III. 4 Opportunity and Unmet Need 9
III. 5 Key Takeaway 10

IV Erectile Dysfunction: Competitive Assessment 11
IV. 1 Overview 11
IV. 2 Strategic Competitor Assessment 11
IV. 3 Product Profile for the Major March keted Products in the Eerectile Dysfunction March ket 12
IV. 3.1 Viagra (sildenafil citrate) 12
IV. 3.2 Cialis (tadalafil) 13
IV. 3.3 Levitra (verdenafil HCL) 14
IV. 3.4 Caverject (Alprostadil) 16
IV. 3.5 Muse (alprostadil) 17
IV. 4 Key Takeaway 18

V Erectile Dysfunction: Pipeline Assessment 19
V. 1 Overview 19
V. 2 Strategic Pipeline Assessment 19
V. 2.1 Technology Trends Analytical Framework 19
V. 3 Erectile Dysfunction Therapeutics - Promising Drugs under Clinical Development 20
V. 4 Drugs under Clinical Development 21
V. 4.1 Avanafil 21
V. 4.2 Zoraxel 22
V. 5 Erectile Dysfunction - Clinical Pipeline by Mechanism of Action 23
V. 6 Erectile Dysfunction - Pipeline by Phases of Clinical Development 23
V. 6.1 Erectile Dysfunction Therapeutics - Phase III Pipeline 24
V. 6.2 Erectile Dysfunction - Phase II Pipeline 24
V. 6.3 Erectile Dysfunction Therapeutics - Preclinical Pipeline 24
V. 7 Discontinued / Suspended Drugs for Erectile Dysfunction 24
V. 8 Key Takeaway 24

VI Erectile Dysfunction March ket: Implications for Future March ket Competition 25

VII Erectile Dysfunction March ket: Future Players in the Erectile Dysfunction March ket 26
VII. 1 Introduction 26
VII. 2 VIVUS, Inc. 26
VII. 2.1 Overview 26
VII. 2.2 Business Overview 27
VII. 2.3 Sexual Dysfunction Portfolio 27
VII. 2.4 Erectile Dysfunction Product Portfolio 28
VII. 3 Rexahn Pharmaceuticals, Inc. 29
VII. 3.1 Overview 29
VII. 3.2 Sexual Dysfunction Portfolio 29
VII. 3.3 ED Product Portfolio 29
VII. 4 Palatin Technologies, Inc. 30
VII. 4.1 Overview 30
VII. 4.2 Business Overview 30
VII. 4.3 Sexual Dysfunction Portfolio 31

VIII Erectile Dysfunction: Appendix 32
VIII. 1 Definitions 32
VIII. 2 Scope of Pipeline Research 32
VIII. 3 Abbreviations 32
VIII. 4 Research Methodology 32
VIII. 4.1 Coverage 33
VIII. 4.2 Secondary Research 33
VIII. 4.3 Forecasted data ing 34
VIII. 4.4 Primary Research 37
VIII. 4.5 Expert Panels 37
VIII. 5 Contact Us 37
VIII. 6 Disclaimer 37
VIII. 7 Sources 38

1.1 List of Data tables
Data table 1: Erectile Dysfunction, Global, March ket Sales s, US$ bn, from 2001 to 2009 6
Data table 2: Erectile Dysfunction March ket, Global, Forecasted data Sales s, US$ bn, from 2009 to 2017 7
Data table 3: Major March keted Products in the Erectile Dysfunction March ket, 2010 18
Data table 4: Erectile Dysfunction Therapeutics - Promising Drugs Under Clinical Development, 2010 20
Data table 5: Erectile Dysfunction - Phase III Clinical Pipeline, 2010 24
Data table 6: Erectile Dysfunction - Phase II Pipeline, 2010 24
Data table 7: Erectile Dysfunction Therapeutics - Preclinical Pipeline, 2010 24
Data table 8: List of Discontinued Drugs for Erectile Dysfunction, 2010 24
Data table 9: VIVUS, Inc. - Sexual Dysfunction and Erectile Dysfunction Pipeline, 2010 27
Data table 10: Rexahn Pharmaceuticals Inc. - Sexual Dysfunction and Erectile Dysfunction Pipeline, 2010 29
Data table 11: Palatin Technologies - Sexual Dysfunction and Erectile Dysfunction Pipeline, 2010 31

1.2 List of Charts
Chart 1: Erectile Dysfunction March ket, Global, Sales s ($bn), 2001-2009 6
Chart 2: Erectile Dysfunction March ket, Global, March ket Forecasted data, US$ bn, from 2009 to 2017 7
Chart 3: Opportunity and Unmet Need in the Erectile Dysfunction March ket, 2010 9
Chart 4: Strategic Competitor Assessment of the March keted Products in Erectile Dysfunction, 2010 11
Chart 5: Technology Trends Analytic Framework of the Erectile Dysfunction Pipeline, 2010 19
Chart 6: Technology Trends Analytic Framework of Erectile Dysfunction Pipeline - Description, 2010 20
Chart 7: Erectile Dysfunction - Clinical Pipeline by Mechanism of Action, 2010 23
Chart 8: Erectile Dysfunction - Pipeline by Phase of Clinical Development, 2010 23
Chart 9: Implications for Future March ket Competition in the Erectile Dysfunction March ket, 2010 25
Chart 10: Erectile Dysfunction Therapeutics March ket - Clinical Pipeline by Firms, 2010 26
Chart 11: GlobalData Methodology 33
Chart 12: GlobalData March ket Forecasted data ing Model 36

Companies mentioned
VIVUS, Inc
Rexahn Pharmaceuticals, Inc
Palatin Technologies, Inc

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Depression – Pipeline Review, H1 2012

Pathology Industry: Depression – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.